SHL is primed to exhibit at the Prefilled Syringe Seminar in Tokyo.
Taking place from 21-22 May, visitors are welcome to stop by SHL¡¯s stand to learn more about its innovations and industry leading offerings.
As a long-standing exhibitors at this annual exhibition, which is hosted by the Parenteral Drug Association (PDA) Japan Chapter, SHL is set on presenting its strong pipeline of auto-injectors designed for high-volume and high-viscosity drug formulations.
Top displays include the Bertha? auto-injector, which is developed to deliver highly viscous drugs in syringe volumes up to 2.25ml. The Maggie? auto-injector will also be available, which is built with Needle Isolation Technology (NIT?), an innovative solution that facilitates a cartridge-based architect while preventing sharps injuries.
SHL¡¯s Molly? family includes Molly? 1ml, Molly? 2.25ml and Molly? C. It showcases SHL¡¯s self-developed, preconfigured technology for faster development timelines.
The rise of protein drugs and biologics in recent years have called for higher demands in SHL¡¯s drug delivery offerings.
Executive director of Business Development Mike Weng commented: ¡°As a leading device manufacturer in the industry for 30 years, SHL is committed to innovation and research that advances our offerings in becoming biologics¡¯ best partner. This year, other than catching up on some industry talks with familiar faces, we are looking forward to expanding ties with potential partners.¡±
Visit SHL at the Sola City Conference Center from 21/22 May, where its experts will be on site to connect with visitors.